{"a":[{"_":"Chutes & Ladders—Former Legend CEO lands at K2","$":{"href":"/biotech/chutes-ladders-former-legend-ceo-lands-role-k2-therapeutics","hreflang":"en"}}]}

Neutral

AI Analysis

Summary

K2 Therapeutics, a 2024-founded startup backed by a $50 million seed round from MPM BioImpact, has appointed Wang as its new CEO. This follows the recent departure of Ying Huang from Legend Biotech.

Importance:3/10

Sentiment:

0.00

management_changeexecutive_appointmentstartup_fundingK2_TherapeuticsLegend_Biotech

Related Companies

$LEGN

Read the original article

Published by FierceBiotech on August 13, 2026 2:26 PM

Read Original